Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 1400 of 2051 entries
View as:

Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)

Phase: N/A Priority: Normal
NCT ID: NCT05609968 Org: User:
Start: 02/06/23 End: 08/23/28 Due: 08/23/29

A Comparison of Measurements of Ketone Body Flux Versus Ketone Body Concentration as a Pharmacodynamic Marker of Hepatic Fatty Acid Oxidation (0000-110)

Phase: N/A Priority: Normal
NCT ID: NCT00860392 Org: User:
Start: 03/02/09 End: 07/08/09 Due: 07/08/10

A Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Doravirine (MK-1439) (MK-1439-019)

Phase: N/A Priority: Normal
NCT ID: NCT02089659 Org: User:
Start: 03/26/14 End: 05/12/14 Due: 05/12/15

Evaluation of the Safety and Immunogenicity of Sequential Administration of Prevnar 13™ and Pneumovax™ 23 in Healthy Participants 50 Years of Age and Older (V110-029)

Phase: N/A Priority: Normal
NCT ID: NCT02225587 Org: User:
Start: 08/28/14 End: 07/06/15 Due: 07/06/16

A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men (V503-020)

Phase: N/A Priority: Normal
NCT ID: NCT02114385 Org: User:
Start: 03/24/14 End: 04/22/15 Due: 04/22/16

Niacin (+) Laropiprant (TREDAPTIVE) Re-examination Study (MK-0524A-119)

Phase: N/A Priority: Normal
NCT ID: NCT01228019 Org: User:
Start: 12/31/10 End: 05/31/13 Due: 05/31/14

To Study Different Levels of MK0493 for Safety, Efficacy, and Tolerability in Obese Patients (0493-017)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00482196 Org: User:
Start: 07/31/05 End: 03/31/06 Due: 03/31/07

A Study of MK-8189 Human Absorption, Metabolism, and Excretion in Healthy Male Participants (MK-8189-010)

Phase: N/A Priority: Normal
NCT ID: NCT06626464 Org: User:
Start: 05/13/22 End: 07/08/22 Due: 07/08/23

Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017)

Phase: N/A Priority: Normal
NCT ID: NCT00110188 Org: User:
Start: 05/31/05 End: 08/31/07 Due: 08/31/08

Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001)

Phase: N/A Priority: Normal
NCT ID: NCT04569786 Org: User:
Start: 10/29/20 End: 02/18/21 Due: 02/18/22

Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)

Phase: N/A Priority: Normal
NCT ID: NCT00479388 Org: User:
Start: 07/31/07 End: 10/31/08 Due: 10/31/09

Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00092196 Org: User:
Start: 12/01/02 End: 12/01/04 Due: 12/01/05

Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013)

Phase: N/A Priority: Normal
NCT ID: NCT02452047 Org: User:
Start: 08/21/15 End: 09/18/17 Due: 09/18/18

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)

Phase: N/A Priority: Normal
NCT ID: NCT06664801 Org: User:
Start: 11/14/24 End: 07/10/26 Due: 07/10/27

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

Phase: N/A Priority: Normal
NCT ID: NCT05947851 Org: User:
Start: 08/08/23 End: 06/27/33 Due: 06/27/34

Post-marketing Surveillance of Children With Chronic Hepatitis C Treated With Intron A (Vial or Pen) and Rebetol (Study P04397)(TERMINATED)

Phase: N/A Priority: Normal
NCT ID: NCT00727077 Org: User:
Start: 06/30/06 End: 06/30/07 Due: 06/30/08

Study of HCV Genotype 1 Patients in the UK Treated With ViraferonPeg and Rebetol (Study P05269)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00724373 Org: User:
Start: 11/30/07 End: 02/28/09 Due: 02/28/10

A Study to Investigate the Antihypertensive Efficacy of MK0954

Phase: N/A Priority: Normal
NCT ID: NCT00887250 Org: User:
Start: 12/31/91 End: 11/30/92 Due: 11/30/93

Substudy 06C: A Study of Sacituzumab Tirumotecan (MK-2870) With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

Phase: N/A Priority: Normal
NCT ID: NCT06469944 Org: User:
Start: 09/20/24 End: 04/12/29 Due: 04/12/30

Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737)

Phase: N/A Priority: Normal
NCT ID: NCT00526474 Org: User:
Start: 09/01/07 End: 12/01/11 Due: 12/01/12

Revaccination With PNEUMOVAX™ 23 in Older Japanese Adults (V110-902)

Phase: N/A Priority: Normal
NCT ID: NCT02260882 Org: User:
Start: 10/31/14 End: 04/09/15 Due: 04/09/16

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

Phase: N/A Priority: Normal
NCT ID: NCT02628067 Org: User:
Start: 12/18/15 End: 05/04/27 Due: 05/04/28

A Study of Two Approved Drugs in Patients With Osteoarthritis (0966-219)

Phase: N/A Priority: Normal
NCT ID: NCT00092352 Org: User:
Start: 04/29/03 End: 12/01/03 Due: 12/01/04

A Long-term Study of ERN/LRPT (Extended Release Niacin/Laropiprant [MK0524A]) in Patients With Dyslipidemia (0524A-102)

Phase: N/A Priority: Normal
NCT ID: NCT00961636 Org: User:
Start: 10/31/09 End: 01/31/11 Due: 01/31/12

Palonosetron Plus Dexamethasone in Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04594)

Phase: N/A Priority: Normal
NCT ID: NCT00687011 Org: User:
Start: 10/10/06 End: 10/27/08 Due: 10/27/09